Clinical Trial Update: Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of pharmacokinetically guided everolimus in patients with breast cancer, pancreatic neuroendocrine tumors, or renal cell carcinoma was terminated;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Gastrinoma
• Glucagonoma
• Pancreatic Neuroendocrine Tumor
• Renal Cell Carcinoma

Drugs mentioned

• Afinitor (everolimus)

Snippet

Sponsor: Emory University | Conditions: Estrogen Receptor-positive Breast Cancer, Gastrinoma | Phase 2 | Status: TERMINATED | Results posted: 2017-02-03